Medpace Holdings, Inc. (MEDP) Stock: Price, Forecast & Analyst Target
Medpace Holdings, Inc. (MEDP) — MoonshotScore 94/100 (Exceptional band), calculated Oct 26, 2026. Price $676.77 (+1.13%), as of the Oct 26, 2026 trading session; market cap $18.9B. Expected results Feb 8, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 26.80× (market value Oct 26, 2026; cash Sep 30, 2026) · expected results Feb 8, 2027
Medpace Holdings, Inc. · MEDP · NASDAQ · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Medpace is an outsourced clinical-development operator serving pharmaceutical, biotechnology and medical-device sponsors, not a diagnostics manufacturer selling tests or instruments. Its appeal rests on whether broad trial execution can resume meaningful growth after revenue recently flattened while preserving strong operating profitability and cash generation.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Medpace Holdings (MEDP)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $716M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 8 of 8
- Altman Z 8.30 · Piotroski F 8
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional |
The score moved from 88 in the stored Oct 24, 2026 snapshot to 94 in the current publication computed Oct 26, 2026 (+6); the largest pillar moves were Momentum -3 and Financial Safety +1.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $676.77 | |
| Change on the day | +1.13% | |
| 52-week range | $373.00–$684.52 | |
| Market capitalisation | $18.9B | |
| Price / earnings (trailing) | 36.45 | |
| Shares traded on the day | 305.5K | |
| Beta (volatility vs the S&P 500) | 1.18 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We will provide guidance for 2027 at the end of our Q4 reporting.
August James Troendle · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Medpace Holdings (MEDP): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the MEDP film — every key number, told as a short cinematic story
~2 min · open the film
What is Medpace Holdings (MEDP), and what does it report?
Short answer · as of
Sponsors hire Medpace to design and manage clinical programs, coordinate laboratories and imaging, handle data and regulatory work, monitor safety, and support submissions and post-marketing studies.
Research dated 2026-09-12.
Sponsors hire Medpace to design and manage clinical programs, coordinate laboratories and imaging, handle data and regulatory work, monitor safety, and support submissions and post-marketing studies. Demand therefore follows the volume and scope of client development programs rather than sales of Medpace-owned therapies.
Reported revenue aggregates that service activity across therapeutic areas. Oncology and metabolic programs are the largest disclosed revenue pools, with cardiology, central nervous system work and other programs adding diversification.
What do the latest results show for Medpace Holdings (MEDP)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $716M.
Research dated 2026-09-12.
Annual revenue and net income rose throughout the period shown, and quarterly revenue advanced sharply before settling into a narrow range recently. In the latest period, gross profit and operating profit improved despite nearly unchanged revenue, while net income and diluted earnings softened modestly.
Reported earnings and revenue have repeatedly exceeded prevailing estimates across recent releases. Management subsequently updated its net-income outlook, incorporating tax, interest-income and repurchase assumptions rather than attributing the latest result to a new operating mechanism.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $716.00M Sep 30, 2026
- Latest quarter · SG&A
- $51.77M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $165.54M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $716.00M | Not available | $51.77M | $165.54M |
| Jun 30, 2026 | $707.33M | Not available | $48.10M | $146.82M |
| Mar 31, 2026 | $706.60M | Not available | $47.92M | $141.50M |
| Dec 31, 2025 | $708.45M | Not available | $44.92M | $153.27M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $716.00M Oct 21, 2026
- Latest report · revenue estimate
- $714.47M Oct 21, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 21, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 21, 2026 | $716.00M | $714.47M | $4.8400 | $4.4400 |
| Jul 22, 2026 | $707.33M | $689.51M | $4.2500 | $3.9800 |
| Apr 22, 2026 | $706.60M | $697.60M | $4.2800 | $3.9200 |
| Feb 9, 2026 | $708.45M | $689.31M | $4.6700 | $4.1900 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $716M | $137M | $4.84 (diluted) |
| Q2 FY2026 | $707M | $121M | $4.25 (diluted) |
| Q1 FY2026 | $707M | $124M | $4.28 (diluted) |
| Q4 FY2025 | $708M | $135M | $4.67 (diluted) |
What are the financial strengths and risks for Medpace Holdings (MEDP)?
Short answer
Cash and short-term investments were $705.32M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $216.60M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow remained positive throughout the quarterly series and generally exceeded capital spending by a wide margin. Cash and short-term investments exceed total debt, leaving Medpace with net cash and substantial internal funding capacity.
Liquidity still deserves scrutiny. Cash has moved sharply between periods and declined across the full reported window, while the current ratio remains below parity and total liabilities exceed the cash balance. The market value also dwarfs net cash, so the valuation depends far more on continued earnings execution than on balance-sheet assets.
A broad slowdown in client clinical-development activity would pressure service demand, with weakness in oncology or metabolic programs carrying particular weight. If revenue remains flat while operating costs rise, the recent benefit from operating leverage would reverse.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $216.60M Sep 30, 2026
- Previous quarter · operating cash flow
- $162.01M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $216.60M | −$20.16M |
| Jun 30, 2026 | $162.01M | −$23.91M |
| Mar 31, 2026 | $151.79M | −$6.81M |
| Dec 31, 2025 | $192.65M | −$4.54M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Medpace Holdings (MEDP)?
Short answer · as of
The next earnings report is expected on Feb 8, 2027.
Research dated 2026-09-12.
Revenue progression is the immediate operating test: recent periods show a plateau after a strong advance. Watch whether gross profit and operating profit can keep improving without renewed top-line momentum, and whether operating cash flow continues to translate accounting earnings into cash.
The scheduled earnings release also provides a direct comparison with expectations for renewed revenue and earnings growth. Beyond that release, consensus estimates assume continued expansion, making any sustained divergence in revenue, margins or cash conversion especially informative.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We will provide guidance for 2027 at the end of our Q4 reporting.
August James Troendle ·
How does Medpace Holdings compare with its peers?
Short answer
Medpace Holdings's score ranks tied for 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Medpace is better understood as an integrated clinical-development partner than as a conventional diagnostics company or a biotechnology developer. It earns service revenue by running client programs across the development lifecycle rather than relying on sales of an owned drug.
Its operating breadth combines trial management with central laboratory work, bio-analytical testing, imaging, electrocardiography, data services, safety monitoring and regulatory support. The therapeutic revenue mix is led by oncology and metabolic programs, so diversification comes from both service breadth and exposure to distinct areas of clinical research.
| Company | Price | Market value | Score |
|---|---|---|---|
| Medpace Holdings (MEDP) — this page | $676.77 | $18.9B | 94 |
| $570.21 Oct 26, 2026 | $44.9B | 94 5-pillar Oct 26, 2026 | |
| $271.04 Oct 26, 2026 | $40.9B | 93 5-pillar Oct 26, 2026 | |
| $50.37 Oct 26, 2026 | $10.4B | 88 5-pillar Oct 26, 2026 | |
| $30.47 Oct 26, 2026 | $12.8B | 86 5-pillar Oct 26, 2026 | |
| $1669.62 Oct 26, 2026 | $33.5B | 84 5-pillar Oct 26, 2026 | |
| $242.95 Oct 26, 2026 | $26.8B | 77 5-pillar Oct 26, 2026 | |
| $68.07 Oct 26, 2026 | $34.7B | 74 5-pillar Oct 26, 2026 | |
| $183.78 Oct 26, 2026 | $14.3B | 73 5-pillar Oct 26, 2026 | |
| $329.90 Oct 26, 2026 | $26.7B | 73 5-pillar Oct 26, 2026 | |
| $160.39 Oct 26, 2026 | $17.9B | 72 5-pillar Oct 26, 2026 | |
| $455.98 Oct 26, 2026 | $44.8B | 66 5-pillar Oct 26, 2026 | |
| $357.27 Oct 26, 2026 | $16.6B | 65 5-pillar Oct 26, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $515.00 – $730.00
- Consensus target
- $639.90
- Median target
- $654.00
Consensus record · Captured .
Measured against a quoted price of $676.77 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 21, 2026
- Transactions
- 60
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 31
- Other transactions
- 29
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 88.6% Period end Jun 30, 2026
- Previous quarter · ownership
- 84.7% Prior to period end Jun 30, 2026
- Reporting holders
- 713 Period end Jun 30, 2026
- Previous quarter · holders
- 743 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 2,498,248 |
| Price T Rowe Associates INC /Md/ | 2,069,677 |
| Aqr Capital Management LLC | 1,278,935 |
| Vanguard Portfolio Management LLC | 1,133,357 |
| Vanguard Capital Management LLC | 1,026,820 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
MEDP Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Medpace actually sell to drug and device developers?
Medpace sells coordinated clinical-development services spanning program design, trial execution, laboratory and imaging support, data management, safety monitoring, regulatory work and post-marketing support. Revenue reflects work performed for sponsors, not commercial sales of Medpace-owned treatments.
Why are oncology and metabolic programs so important to Medpace?
Oncology and metabolic work form the largest disclosed therapeutic revenue pools. Changes in sponsor activity across those programs can therefore have an outsized effect on Medpace’s overall growth.
How capital intensive is Medpace’s clinical-development model?
Capital spending has generally remained modest beside operating cash flow, indicating that recent growth has not required comparable investment in physical assets. The latest rise in spending is worth tracking because persistence would change that cash-conversion profile.
What would break Medpace’s recent earnings pattern?
Sustained weakness in contracted clinical-development activity, especially across the largest therapeutic programs, would remove the revenue support behind operating leverage. Margin deterioration or weaker cash conversion during a revenue plateau would provide an early sign that the pattern has changed.
What is the MEDP stock price today?
The last price recorded on this page for Medpace Holdings, Inc. (MEDP) is $676.77, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MEDP price target?
The analyst consensus price target for Medpace Holdings, Inc. (MEDP) is $639.90 (range $515.00 to $730.00, median $654.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (79 figures)
The 79 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | August James Troendle (Oct 22, 2026): We will provide guidance for 2027 at the end of our Q4 reporting. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Cincinnati, OH | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "5375 Medpace Way, Cincinnati, OH, 45227, US". |
FMP — 70 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Feb 8, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $676.77 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T20:34:30.161Z. | |
px.change | Change on the day | +1.13% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $18.9B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:01.000Z. Captured from FMP at 2026-10-26T20:34:28.489Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$7.58 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q3 FY2026 | $716M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $373.00–$684.52 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 36.45 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 305.5K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.18 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | August James Troendle | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 6,500 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $1.14B, net result $181.85M; FY2022 revenue $1.46B, net result $245.37M; FY2023 revenue $1.89B, net result $282.81M; FY2024 revenue $2.11B, net result $404.39M; FY2025 revenue $2.53B, net result $451.12M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Other $408.55M · Oncology $747.59M · Metabolic $744.96M · Cardiology $239.37M · Central Nervous System $254.84M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 29.1% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-09-30.revenue_k | Revenue — period end 2026-09-30 | $716.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-09-30.sga_k | SG&A — period end 2026-09-30 | $51.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-09-30.operating_result_k | FMP standardized operating result — period end 2026-09-30 | $165.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $707.33M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $48.10M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $146.82M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $706.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $47.92M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $141.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $708.45M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $44.92M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $153.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-10-21.revenue_actual | Revenue · reported — report date 2026-10-21 | $716.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-10-21.revenue_estimated | Revenue · estimate — report date 2026-10-21 | $714.47M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-10-21.eps_actual | EPS · reported — report date 2026-10-21 | $4.8400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-10-21.eps_estimated | EPS · estimate — report date 2026-10-21 | $4.4400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-22.revenue_actual | Revenue · reported — report date 2026-07-22 | $707.33M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-22.revenue_estimated | Revenue · estimate — report date 2026-07-22 | $689.51M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-22.eps_actual | EPS · reported — report date 2026-07-22 | $4.2500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-22.eps_estimated | EPS · estimate — report date 2026-07-22 | $3.9800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-22.revenue_actual | Revenue · reported — report date 2026-04-22 | $706.60M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-22.revenue_estimated | Revenue · estimate — report date 2026-04-22 | $697.60M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-22.eps_actual | EPS · reported — report date 2026-04-22 | $4.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-22.eps_estimated | EPS · estimate — report date 2026-04-22 | $3.9200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-09.revenue_actual | Revenue · reported — report date 2026-02-09 | $708.45M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-09.revenue_estimated | Revenue · estimate — report date 2026-02-09 | $689.31M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-09.eps_actual | EPS · reported — report date 2026-02-09 | $4.6700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-09.eps_estimated | EPS · estimate — report date 2026-02-09 | $4.1900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q3 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $705.32M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $216.60M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-09-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $146.04M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 31.96× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-09-30.operating_cash_flow_m | Operating cash flow — period end 2026-09-30 | $216.60M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $162.01M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-09-30.capex_m | Capital expenditure (reported) — period end 2026-09-30 | −$20.16M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$23.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $151.79M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$6.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $192.65M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$4.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $515.00 – $730.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $639.90 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $654.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 60 transactions · 0 purchases, 31 sales, 29 other transactions · 7 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 21, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 88.6% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 84.7% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 713 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 743 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 2,498,248 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 2,069,677 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Aqr Capital Management LLC — shares in provider snapshot | 1,278,935 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 1,133,357 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Capital Management LLC — shares in provider snapshot | 1,026,820 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-22 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 8.30 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 26.80× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $705.32M at Sep 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-26. Balance-sheet reference date: 2026-09-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-10-21.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($716.00M) with the recorded estimate ($714.47M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-10-21.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($4.8400) with the recorded estimate ($4.4400) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 94 of 100 · Exceptional · pillars 95 / 71 / 43 / 95 / 88 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 88 (stored snapshot Oct 24, 2026) → 94 (current publication computed Oct 26, 2026) (+6) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-09-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-09-30.revenue_k,fin.q_table.depth.2026-09-30.sga_k,fin.q_table.depth.2026-09-30.operating_result_k,fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k. - Earnings-history note. Source series as of 2026-10-21. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-10-21.revenue_actual,earn.history.depth.2026-10-21.revenue_estimated,earn.history.depth.2026-10-21.revenue_actual.comparison,earn.history.depth.2026-10-21.eps_actual.comparison,earn.history.depth.2026-10-21.eps_actual,earn.history.depth.2026-10-21.eps_estimated,earn.history.depth.2026-07-22.revenue_actual,earn.history.depth.2026-07-22.revenue_estimated,earn.history.depth.2026-07-22.eps_actual,earn.history.depth.2026-07-22.eps_estimated,earn.history.depth.2026-04-22.revenue_actual,earn.history.depth.2026-04-22.revenue_estimated,earn.history.depth.2026-04-22.eps_actual,earn.history.depth.2026-04-22.eps_estimated,earn.history.depth.2026-02-09.revenue_actual,earn.history.depth.2026-02-09.revenue_estimated,earn.history.depth.2026-02-09.eps_actual,earn.history.depth.2026-02-09.eps_estimated. - Cash-flow note. Source series as of 2026-09-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-09-30.operating_cash_flow_m,fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-09-30.capex_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Medpace Holdings, Inc. | 2026-02-10 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-10 |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 8731 — Services-Commercial Physical & Biological Research. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Revenue by segment | Other: $408.55M; Oncology: $747.59M; Metabolic: $744.96M; Cardiology: $239.37M; Central Nervous System: $254.84M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-22 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-23 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash, investments and debt | Total debt: $120.10M; Liquidity basis: cash and short-term investments; Total liabilities: $1.62B; Cash and short-term investments: $502.69M; Cash and investments: $502.70M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $502.70M; Cash and short-term investments: $502.70M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $502.70M; Decline: $154.20M; Opening balance: $656.90M; Average change per period: $22.00M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $382.60M; Total debt: $120.10M; Cash and investments: $502.70M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 0.73; Current ratio: 0.73; Debt to equity: 0.28; Net margin: 17.7%; Gross margin: 28.8%; Operating margin: 21%; Return on assets: 23.9%; Return on equity: 110.1% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-10-28; EPS estimate: $4.45 per share; Revenue estimate: $714.27M The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold MEDP
Funds in our ETF coverage that list MEDP among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ERShares Private-Public Crossover ETF (XOVR) | 3.17% | |
| Invesco S&P MidCap Quality ETF (XMHQ) | 2.71% |